PRIMARY OBJECTIVES:
I. To assess the safety of neo-adjuvant pembrolizumab in patients with locally advanced
(unresectable primary cancer or resectable primary cancer with a high chance of recurrence)
mismatch repair protein deficiency (dMMR) solid organ tumors by Common Terminology Criteria
for Adverse Events (CTCAE) assessed toxicity and post-surgical complication assessment by the
Clavien-Dindo classification.
II. To assess the rate of complete pathological response for patients who undergo surgical
resection following at least 3 doses of neoadjuvant pembrolizumab.
SECONDARY OBJECTIVES:
I. To quantify the rate of organ sparing at 1 year for all patients treated with one dose of
pembrolizumab (intent to treat) and those patients who receive at least 3 doses of
neoadjuvant pembrolizumab and decline to undergo surgical resection and opt to continue
receiving pembrolizumab for a total of 1 year.
II. To assess radiographic tumor response to neoadjuvant pembrolizumab. III. To estimate the
relapse-free survival and overall survival in all enrolled participants.
IV. To determine the overall rates of pathological response to neoadjuvant pembrolizumab.
V. To assess the rate of complete pathological response (intent to treat) for patients who
undergo surgical resection following at least 1 dose of neoadjuvant pembrolizumab.
OUTLINE:
Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles repeat
every 21 days for 1 year in the absence of disease progression or unacceptable toxicity.
Patients who do not respond to pembrolizumab and stop the treatment after 2 doses may undergo
surgery within 6 months.
After completion of study treatment, patients are followed up at 30 days, every 6 weeks for 1
year, every 12 weeks, and then every 6 months for up to 2 years.
Inclusion Criteria:
- Histologically confirmed diagnosis of solid cancer
- Solid cancer that is deficient in mismatch repair (dMMR) or microsatellite instability
high (MSI-H) as determined by one of three methods:
- Immunohistochemistry determined dMMR by complete loss of MLH1, PMS2, MSH2 or MSH6
- Polymerase chain reaction (PCR) determined microsatellite instability at > 30% of
tested microsatellites
- Next-generation determined MSI-H based upon instability at multiple
microsatellites as determined by the specific next generation sequencing panel
- Locally advanced cancer defined as either an unresectable primary cancer or a
resectable primary cancer with a high chance of recurrence (defined as an estimated
greater or equal to 20% chance of recurrence by the treating physician). A resectable
primary may include locoregional disease, as long as all disease is felt by the
treating physician to be in a resectable distribution
- The participant (or legally acceptable representative if applicable) provides written
informed consent for the trial
- Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)
version (v)1.1 (unless discussed and approved by study principal investigator [PI])
- Have available archival tumor tissue. Availability will be met as long as a request to
obtain formalin-fixed, paraffin embedded (FFPE) tissue blocks (preferred) or slides
has been made (unless discussed and approved by study PI)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Evaluation of ECOG is to be performed within 7 days prior to the date of signing study
consent
- A female participant is eligible to participate if she is not pregnant, not
breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance during the treatment
period and for at least (120 days [corresponding to time needed to eliminate any
study treatment(s) plus 30 days (a menstruation cycle) for risk of genotoxicity])
after the last dose of study treatment
- Absolute neutrophil count (ANC) >= 1500/uL (within 14 days prior to the start of study
treatment)
- Platelets >= 100 000/uL (within 14 days prior to the start of study treatment)
- Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/La (within 14 days prior to the start of study
treatment)
- Creatinine OR measured or calculated creatinine clearance (glomerular filtration rate
[GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) =< 1.5 x
upper limit of normal (ULN) OR >= 30 mL/min for participant with creatinine levels >
1.5 x institutional ULN (within 14 days prior to the start of study treatment)
- Total bilirubin 1.5 x ULN OR direct bilirubin ULN for participants with total
bilirubin levels > 1.5 x ULN (within 14 days prior to the start of study treatment)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x
ULN (=< 5 x ULN for participants with liver metastases) (within 14 days prior to the
start of study treatment)
- International normalized ratio (INR) OR prothrombin time (PT) activated partial
thromboplastin time (aPTT) =< 1.5 x ULN unless participant is receiving anticoagulant
therapy as long as PT or aPTT is within therapeutic range of intended use of
anticoagulants (within 14 days prior to the start of study treatment)
Exclusion Criteria:
- A WOCBP who has a positive urine pregnancy test within 72 hours prior to enrollment.
If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
test will be required. Note: in the event that 72 hours have elapsed between the
screening pregnancy test and the first dose of study treatment, another pregnancy test
(urine or serum) must be performed and must be negative in order for subject to start
receiving study medication
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
CTLA-4, OX 40, CD137)
- Has received prior systemic anti-cancer therapy including investigational agents
within 2 weeks of study treatment. Note: Participants must have recovered from all
adverse events (AEs) due to previous therapies to grade 1 or baseline. Participants
with grade 2 neuropathy may be eligible
- If participant received major surgery, they must have recovered adequately from the
toxicity and/or complications from the intervention prior to starting study treatment
- Has received prior radiotherapy within 2 weeks of start of study treatment.
Participants must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system
(CNS) disease
- Has received a live vaccine within 30 days prior to the first dose of study drug.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
are generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (e.g., FluMist ) are live attenuated vaccines and are not allowed
- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment. Note: Participants who have entered the follow-up phase of an
investigational study may participate as long as it has been 4 weeks after the last
dose of the previous investigational agent
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug
- Has a known additional malignancy that is progressing or has required active treatment
within the past 1 year. Note: Participants with basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,
cervical cancer in situ) or other similar good prognosis cancer with recurrence rates
expected to be < 10% that have undergone potentially curative therapy are not excluded
- Known metastatic sites of disease. Note: locoregional lymph nodes or tumor deposits
are not considered metastatic disease
- Has severe hypersensitivity (grade 3) to pembrolizumab and/or any of its excipients
- Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment
- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis
- Has an active infection requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV)
- Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]
reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid [RNA]
[qualitative] is detected) infection. Note: no testing for hepatitis B and hepatitis C
is required unless mandated by local health authority
- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial
- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of trial treatment
